Mer

Home / Bronchicine CAe®

Bronchicine CAe®

is unlike any other Bordetella bronchiseptica vaccine.

When you look at your options for Bordetella bronchiseptica vaccines, one stands out. BRONCHICINE CAe is the only killed (non-infectious) canineBordetella bronchiseptica vaccine on the market.1 BRONCHICINE CAe is safe, effective and easy to administer, and it provides veterinarians and pet owners with peace of mind.

BRONCHICINE CAe is the only parenteral B. bronchiseptica vaccine for dogs.

Bordetella pertussis and B. bronchiseptica are closely related.2

The presence of vaccine-induced serum antibodies is a good correlate of immunity against B. pertussis in children3 and against B. bronchiseptica in dogs.4

Effective and Safe

Less than 1 lack of efficacy reported per 10,000 doses.5

Parenterally administered BRONCHICINE CAe vaccine has been demonstrated to have a low rate of AEs associated with administration.

Less than 1 AE reported per 10,000 doses.5

IMPORTANT NOTICE!

Please note that this is a general product information according to US approvals, for specific regulatory information concerning your market please contact Regulatory department email: Regulatory.AffairsMER@zoetis.com

Close

Expand All
  • Key Benefits

    BRONCHICINE CAe is licensed for the vaccination of healthy dogs 8 weeks of age or older as an aid in the control of canine infectious tracheobronchitis (kennel cough) caused by Bordetella bronchiseptica.

    BRONCHICINE CAe is a killed cellular antigen extract of the Bordetella bronchiseptica microorganism.

    BRONCHICINE CAe is prepared from antigenic material extracted from B. bronchiseptica. An immunogenic strain of B. bronchiseptica is grown to a high yield, then subjected to a proprietary process that extracts the antigens from the B. bronchiseptica cells. The residual cell debris is then removed, resulting in a product that retains the desirable immunologic qualities of a whole cell vaccine, while helping reduce undesirable adverse events (AEs).

  • Dosage & Adminstration

    Directions: Shake well. Aseptically administer 1 mL subcutaneously. Healthy dogs should receive 2 doses administered 2-4 weeks apart. Annual revaccination with a single dose is recommended.

    The effect of persisting B. bronchiseptica maternal antibody on the immune response in puppies to the bacterin has not been determined. Puppies from bitches immune to the organism usually have low antibody titers that are dissipated by 4-6 weeks of age. Although kennel cough is considered a disease of complex etiology, it can be reproduced by challenge with B. bronchiseptica alone. A close association and/or confinement of dogs facilitates spread of the disease syndrome. Antibiotic therapy has been shown to be generally unsuccessful in reducing or eliminating B. bronchiseptica in dogs.

  • Precautions

    Store at 2°-7°C (35°-45°F). Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Sterilized syringes and needles should be used to administer this vaccine. Transient local irritation at the site of injection, though rare, may occur subsequent to use of this product. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy

  • References

    1.American Animal Hospital Association. 2011 AAHA canine vaccine guidelines. Available at:https://www.aahanet.org/PublicDocuments/CanineVaccineGuidelines.pdf. Accessed August 21, 2013.

    2.Parkhill J, Sebaihia M, Preston A, et al. Comparative analysis of genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet. 2003;35(1):32-40.

    3.Cherry JD, Gombein J, Heinginger U, Stehr K. A search of serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 1998;16(20):1901-1906.

    4.Ellis JA, Hanes DM, West KH, et al. Effect of vaccination on experimental infection with Bordetella bronchiseptica in dogs. JAVMA. 2001;218(3):367-375.

    5.Data on file, 2012 Pharmacovigilance Data, Zoetis Inc.

    6.AVMA PLIT lists top claims for business insurance [JAVMA News]. October 15, 2012. Available at: https://www.avma.org/news/JAVMAnews/pages/121015m.aspx. Accessed August 21, 2013.